Zenosense, Inc. announced that the company has extended its agreement with the Sgenia Group to include cancer sensory devices. Under the terms of the extension, Zenosense has the optional right to fund the development of prospective cancer sensory devices that may be based on the Sgenia technology. Subject to providing funding, the company will have the right to manufacture, market and sell the resulting devices(s), if developed.

The company believes the sensory technology and algorithmic processing in development for MRSA detection could, if successful, be applied to certain cancer sensory devices. Some cancers, such as lung and colon, produce volatile organic compounds in an individual's breath in a similar way to patients infected with MRSA. Should the cancer specific pattern of VOCs be identified, the company believes that a relatively straightforward modification of a successful MRSA detection technology may enable it to produce a similar device for the detection of certain cancers.